Kynam Capital Management, LP - Aug 10, 2023 Form 3 Insider Report for 2seventy bio, Inc. (TSVT)

Role
10%+ Owner
Signature
KYNAM CAPITAL MANAGEMENT, LP, By: KYNAM CAPITAL MANAGEMENT GP, LLC, By: /s/ Yue Tang, Yue Tang, Managing Member
Stock symbol
TSVT
Transactions as of
Aug 10, 2023
Transactions value $
$0
Form type
3
Date filed
8/14/2023, 08:41 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TSVT Common Stock, par value $0.0001 per share 5.52M Aug 10, 2023 See Footnote F1
holding TSVT Common Stock, par value $0.0001 per share 5.06M Aug 10, 2023 Direct F2, F3
holding TSVT Common Stock, par value $0.0001 per share 5.06M Aug 10, 2023 See Footnote F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are owned directly by Kynam Global Healthcare Master Fund, LP (the "Master Fund"), a private investment fund managed by Kynam Capital Management, LP (the "Adviser"), and separately managed account clients of the Adviser and may be deemed to be indirectly beneficially owned by (i) the Adviser, (ii) Kynam Capital Management GP, LLC (the "Adviser GP"), the general partner of the Adviser and (iii) Yue Tang, the managing member of the Adviser GP. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 At the time the Master Fund became a Reporting Person on this Form 3, the Master Fund and separately managed account clients of the Adviser collectively directly owned 5,853,825 shares of Common Stock, par value $0.0001 per share of 2seventy bio, Inc. and the Adviser, the Adviser GP and Yue Tang may have been deemed to indirectly beneficially owned 5,853,825 shares of Common Stock, par value $0.0001 per share of 2seventy bio, Inc. Reference is made to the Form 4 filed by the Reporting Persons on August 14, 2023. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 The reported securities are directly owned by the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F4 The reported securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by Kynam Fund GP, LLC, the general partner of the Master Fund. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose